Thus, dissecting the individual functions of KRAS mutant isoforms in the context of NSCLC is critical to inform combination partners to maximise the effectiveness of direct KRAS inhibitors in this disease setting. This evidence concerns the gene KRAS and non-small cell lung carcinoma.